SLC16A1 and non-Hodgkin lymphoma: Together, these data support the clinical evaluation of AZD3965 in MCT1 expressing DLBCL, NHL and Burkitt’s lymphoma either as monotherapy or in combination with either metabolic pathway inhibition and/or incorporation into R-CHOP based strategies.